Please assess the completion status of the following clinical trial:

Trial Title: S0011, Gene Therapy & Surgery Followed by Chemo & RT in Newly Diagnosed Cancer of the Mouth or Throat

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed high-risk/limited stage III or IV squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, and larynx~  * Newly diagnosed~ * Previously untreated~ * Considered surgically resectable~ * Evidence of regional lymph node metastases (N1-N3)~* No distant metastases~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Not specified~Life expectancy:~* Not specified~Hematopoietic:~* WBC at least 3,000/mm\^3~* Granulocyte count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 2 times upper limit of normal (ULN)~* SGOT or SGPT no greater than 3 times ULN~* Hepatitis B surface antigen negative~* Hepatitis C antibody negative~Renal:~* Creatinine no greater than 2 times ULN~* Creatinine clearance at least 60 mL/min~Other:~* Magnesium normal (magnesium supplement allowed)~* No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or adequately treated stage I or II cancer in complete remission~* HIV negative~* Not pregnant or nursing~* Patients must use effective barrier contraception and prevent bodily fluid transmission during and for 28 days after Ad5CMV-p53 gene administration~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* Not specified~Endocrine therapy:~* Not specified~Radiotherapy:~* No concurrent intensity-modulated radiotherapy~Surgery:~* Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- surgery with INGN 201 followed by chemo/RT (Type: EXPERIMENTAL): intraoperative and postoperative injections of INGN 201 into the tumor bed, followed by cisplatin and radiation therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).